[CAS NO. 611168-24-2] Glycerol phenylbutyrate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [611168-24-2]

Catalog

HY-B2087

Brand

MCE

CAS

611168-24-2

DESCRIPTION [611168-24-2]

Overview

MDL	MFCD28016960
Molecular Weight	530.65
Molecular Formula	C33H38O6
SMILES	O=C(CCCC1=CC=CC=C1)OC(COC(CCCC2=CC=CC=C2)=O)COC(CCCC3=CC=CC=C3)=O

For research use only. We do not sell to patients.

Summary

Glycerol phenylbutyrate is a sigma-2 (σ2) receptor ligand, with a pK _i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug ^[1] ^[2] .

IC50 & Target

σ2 receptor ^[1] .

In Vivo

Glycerol phenylbutyrate (GPB) has the potential for the treatment of hyperammonemia. Glycerol phenylbutyrate (GPB) may have therapeutic potential in additional conditions such as chronic hepatic encephalopathy or other inherited metabolic disorders ^[1] ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05019417	Kaplan Medical Center\|Weizmann Institute of Science	Monocarboxylate Transporter 8 Deficiency	June 30, 2021	Phase 2\|Phase 3
NCT00977600	Horizon Pharma Ireland, Ltd., Dublin Ireland\|Ucyclyd Pharma, Inc.	Healthy	March 2005	Phase 1
NCT01949766	University of Pittsburgh	Byler Disease
NCT00551200	Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	October 2007	Phase 2
NCT02046434	University of Colorado, Denver	Parkinson´s Disease	January 2014	Phase 1
NCT01257737	Horizon Therapeutics, LLC\|Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	October 4, 2010	Phase 4
NCT01347073	Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	July 2011	Phase 3
NCT04937062	Weill Medical College of Cornell University\|Children´s Hospital Colorado\|SLC6A1 Connect\|STXBP1 Foundation\|Clara Inspired\|University of Pennsylvania Orphan Disease Center\|Horizon Therapeutics	STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder	March 1, 2021	Early Phase 1
NCT00986895	Horizon Pharma Ireland, Ltd., Dublin Ireland\|Ucyclyd Pharma, Inc.	Hepatic Encephalopathy\|Urea Cycle Disorders	September 2006	Phase 1
NCT00947297	Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	November 2009	Phase 3
NCT00947544	Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	March 2010	Phase 2
NCT00992459	Horizon Pharma Ireland, Ltd., Dublin Ireland	Urea Cycle Disorders	October 2009	Phase 3
NCT00999167	Horizon Pharma Ireland, Ltd., Dublin Ireland	Cirrhosis\|Hepatic Encephalopathy	December 2009	Phase 2
NCT01135680	Horizon Pharma Ireland, Ltd., Dublin Ireland	Drug Toxicity	May 2010	Phase 1

Appearance

Oil

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 150 mg/mL ( 282.67 mM )

Ethanol : 50 mg/mL ( 94.22 mM ; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8845 mL	9.4224 mL	18.8448 mL
5 mM	0.3769 mL	1.8845 mL	3.7690 mL
10 mM	0.1884 mL	0.9422 mL	1.8845 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.25 mg/mL (4.24 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.25 mg/mL (4.24 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzenebutanoic acid, 1,1′,1′′-(1,2,3-propanetriyl) ester

Benzenebutanoic acid, 1,2,3-propanetriyl ester

Tri(4-phenylbutyryl)glycerol

Glycerol phenylbutyrate

HPN 100

Ravicti

1,2,3-propanetriyl tris(4-phenylbutanoate)